This article examines the activities of national and international actors in Pharmaceutical Services (PS) in Mozambique from 2007 to 2012, focusing on the public provision of HIV/Aids, malaria and tuberculosis medicines. It describes how PS functions in the country, what actors are involved in this ...area and the relations among them, pursuing salient issues in the modus operandi of partners in cooperation.
more
Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4).
Patel V, Chisholm D, Dua T, et al., editors.
Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016 Mar 14.
This is the first global report on epilepsy summarizing the available evidence on the burden of epilepsy and the public health response required at global, regional and national levels.
The reports highlights major gaps in awareness, diagnosis, treatment, and health policies through a series of a...ppalling numbers. With around 50 million people affected worldwide, epilepsy is one of the most common and serious brain disorders. Nearly 80% of people with epilepsy live in low-income and middle-income countries
more
Policy Brief
published: 16 March 2018 doi: 10.3389/fpubh.2018.00069
Training for Health Care Providers
Facilitators’ Manual
4th Edition 2018
National Malaria Elimination & Aedes Transmitted Disease Control Program
Disease Control Unit Directorate General of Health Services
HIV/TB workplace policy and Implementation Strategy
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...tems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
more
The 2023 update of the Global Strategy for Asthma Management and Prevention incorporates new scientific information about asthma based on a review of recent scientific literature by an international panel of experts on the GINA Science Committee. This comprehensive and practical resource about one o...f the most common chronic lung diseases worldwide contains extensive citations from the scientific literature and forms the basis for other GINA documents and programs.
more
Infectious Diseases of Poverty 2014, 3:42
http://www.idpjournal.com/content/3/1/42
Due to the anticipated significant rise in VL testing occasioned by Ghana’s adaptation of 2016 ART guidelines, it has become necessary to develop this VL scale-up and operational plan to assure complete client access to laboratory monitoring towards the achievement of the third 90 of the HIV care ...cascade. The plan will enhance VL testing, monitoring whilst improving the clinical and laboratory interface for improved client care.
more
Guidelines approved by the WHO Guidelines -Review Committee; second edition
Q8.SCOPING QUESTION: In adults and older adolescents with depressive disorder, what is the comparative effectiveness of different formats of psychological treatments?
In Kenya, the bacterial infections that contribute most to human disease are often those in which re-‐sistance is most evident. Examples are multidrug-‐resistant enteric bacterial pathogens such as typhoid, ... diarrhoeagenic Escherichia coli and invasive non-‐typhi salmonella, penicillin-‐resistant Streptococcus pneu-‐moniae, vancomycin-‐resistant enterococci, methicillin-‐resistant Staphylococcus aureus and multidrug-‐re-‐sistant Mycobacterium tuberculosis. Resistance to medicines commonly used to treat malaria is of particu-‐lar concern, as is the emerging resistance to anti-‐HIV drugs. Often, more expensive medicines are required to treat these infections, and this becomes a major challenge in resource-‐poor settings.
more